Vitamin D for the treatment of osteoporosis

1997 ◽  
Vol 7 (S3) ◽  
pp. 155-158 ◽  
Author(s):  
T. Nakamura
Keyword(s):  
Vitamin D ◽  
Treatment Of Osteoporosis

Non HRT Options for the Treatment of Osteoporosis

1998 ◽  
Vol 4 (3) ◽  
pp. 96-101
Author(s):  
Michael Davies
Keyword(s):  
Vitamin D ◽  
Vertebral Fracture ◽  
Bone Fractures ◽  
The Elderly ◽  
Long Bone ◽  
Mineral Density ◽  
Treatment Of Osteoporosis ◽  
Supplemental Calcium ◽  
Treatable Condition

Osteoporosis is now a treatable condition with an abundance of evidence for the efficacy of certain therapeutic strategies in preventing recurrent fractures. Most of these treatments act by improving bone mineral density through inhibition or reduction of bone resorption. For those women who are unable to take HRT; bisphosphonates, calcium, vitamin D, calcitriol or calcitonin may confer certain benefits. The bisphosphonate alendronate reduces both vertebral and long bone fractures, an effect seen soon after starting treatment. The changes in BMD and fracture reduction are less with the use of etidronate but it is certainly beneficial in reducing recurrent vertebral fracture. In the elderly calcium and vitamin D in combination can reduce non-vertebral and hip fracture and supplemental calcium of 1 g/day has been predicted to reduce bone loss and thus hip fractures by 22%. Evidence that calcitriol or calcitonin reduce fracture incidence is not good but calcitonin has been shown to have analgesic properties in those with acute vertebral fracture. The role of calcitriol is less certain and should be reserved for women with vertebral fractures in whom HRT or bisphosphonates cannot be used.

scholarly journals An overview on the treatment of postmenopausal osteoporosis

2014 ◽  
Vol 58 (2) ◽  
pp. 162-171 ◽  
Author(s):  
Sergio Setsuo Maeda ◽  
Marise Lazaretti-Castro
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Pharmacological Treatment ◽  
Bone Cells ◽  
Treatment Of Osteoporosis ◽  
Drug Intolerance ◽  
Active Medication ◽  
Novel Drugs ◽  
Substantial Morbidity

Osteoporosis is a worldwide health problem related to the aging of the population, and it is often underdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporosis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti-resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials.

Vitamin D and its Metabolites in the Treatment of Osteoporosis

1998 ◽  
Vol 8 (S2) ◽  
pp. S40-S44
Author(s):  
P. Burckhardt ◽  
O. Lamy
Keyword(s):  
Vitamin D ◽  
Treatment Of Osteoporosis

The Special Role of ``Hormonal'' Forms of Vitamin D in the Treatment of Osteoporosis

1999 ◽  
Vol 65 (4) ◽  
pp. 307-310 ◽  
Author(s):  
B. E. C. Nordin ◽  
A. G. Need ◽  
H. A. Morris ◽  
M. Horowitz
Keyword(s):  
Vitamin D ◽  
Special Role ◽  
Treatment Of Osteoporosis

scholarly journals Vitamin D3 Treatment Alters Thyroid Functional Morphology in Orchidectomized Rat Model of Osteoporosis

2022 ◽  
Vol 23 (2) ◽  
pp. 791
Author(s):  
Branka Šošić-Jurjević ◽  
Svetlana Trifunović ◽  
Jasmina Živanović ◽  
Vladimir Ajdžanović ◽  
Marko Miler ◽  
...  
Keyword(s):  
Vitamin D ◽  
Thyroid Hormones ◽  
Functional Morphology ◽  
Rat Model ◽  
Cell Subpopulation ◽  
Treatment Of Osteoporosis ◽  
Hormone Synthesis ◽  
Fine Regulation ◽  
Induced Changes ◽  
Group Concentration

Vitamin D plays an essential role in prevention and treatment of osteoporosis. Thyroid hormones, in addition to vitamin D, significantly contribute to regulation of bone remodeling cycle and health. There is currently no data about a possible connection between vitamin D treatment and the thyroid in the context of osteoporosis. Middle-aged Wistar rats were divided into: sham operated (SO), orchidectomized (Orx), and cholecalciferol-treated orchidectomized (Orx + Vit. D3; 5 µg/kg b.m./day during three weeks) groups (n = 6/group). Concentration of 25(OH)D in serum of the Orx + Vit. D3 group increased 4 and 3.2 times (p < 0.0001) respectively, compared to Orx and SO group. T4, TSH, and calcitonin in serum remained unaltered. Vit. D3 treatment induced changes in thyroid functional morphology that indicate increased utilization of stored colloid and release of thyroid hormones in comparison with hormone synthesis, to maintain hormonal balance. Increased expression of nuclear VDR (p < 0.05) points to direct, TSH independent action of Vit. D on thyrocytes. Strong CYP24A1 immunostaining in C cells suggests its prominent expression in response to Vit. D in this cell subpopulation in orchidectomized rat model of osteoporosis. The indirect effect of Vit. D on bone, through fine regulation of thyroid function, is small.

scholarly journals Preporuke za oboljele od osteoporoze i liječnike obiteljske medicine u doba COVID-19 pandemije

2020 ◽  
Vol 44 (3) ◽  
pp. 165-170
Author(s):  
Blaženka Miškić ◽  
Željka Dujmić ◽  
Ines Rajkovača-Latić ◽  
Karla Miškić ◽  
Aleksandar Včev ◽  
...  
Keyword(s):  
Vitamin D ◽  
General Practitioner ◽  
Medical Treatment ◽  
General Practitioners ◽  
Multidisciplinary Team ◽  
Physical Activities ◽  
Regular Exercise ◽  
Civil Protection ◽  
Treatment Of Osteoporosis ◽  
Increase Risk

The paper presents the guidelines made by the Multidisciplinary Team for Osteoporosis for patients in the General Hospital “Dr.Josip Benčević”, Slavonski Brod and general practitioners in the Brod-Posavina County in order to inform them properly about the COVID-19 pandemic and the recommendations of the National Civil Protection Committee, as well as to help them reduce their fear and to improve their cooperation with their general practitioners. A system of recording new fractures in the county was maintained since the onset of the epidemic. The recommendations for patients with osteoporosis include their lifestyle, medical treatment and balanced nutrition, following the advices of the International Osteoporosis Foundation, the Croatian Osteoporosis Society and the British Royal Osteoporosis Society. Living with osteoporosis demands balanced nutrition, regular exercise and taking prescribed medications. As in the present conditions of COVID-19 epidemic outdoor physical activities are temporarily limited it is necessary to ensure the availability of calcium-rich food and vitamin D supplies. As medical treatment of osteoporosis does not increase risk of COVID-19 infection it is recommended for patients to continue their prescribed therapy in consultation with their general practitioner.

scholarly journals Alfacalcidol is the optimal vitamin D preparation for the treatment of osteoporosis in patients older than 45 years

2017 ◽  
Vol 19 (2) ◽  
pp. 163-166
Author(s):  
I.S. Dydykina ◽  
◽  
P.S. Kovalenko ◽  
A.A. Kovalenko ◽  
Keyword(s):  
Vitamin D ◽  
Treatment Of Osteoporosis

scholarly journals New Molecules Modulating Bone Metabolism – New Perspectives in the Treatment of Osteoporosis

2017 ◽  
pp. S341-S347 ◽  
Author(s):  
I. ZOFKOVA ◽  
J. BLAHOS
Keyword(s):  
Vitamin D ◽  
Osteoblast Differentiation ◽  
Bone Microstructure ◽  
Bmp Signaling ◽  
Vitamin D Metabolites ◽  
Anabolic Effect ◽  
Epigenetic Mechanisms ◽  
Direct Effects ◽  
Treatment Of Osteoporosis ◽  
Osteoblast Activity

In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, as well as a drug with an anabolic effect on the skeleton, parathormone. However, there is also a focus on non-traditional strategies used in therapy for osteolytic diseases. The newest antiosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic differentiation of mesenchymal stem cells through Wnt/β-catenin (icarrin, isoflavonoid caviunin, or sulfasalazine). A certain promise in the treatment of osteoporosis is shown by molecules targeting non-coding microRNAs (which are critical for osteoclastogenesis) or those stimulating osteoblast activity via epigenetic mechanisms. Vitamin D metabolites have specific antiosteoporotic potencies, modulating the skeleton not only via mineralization, but markedly also through the direct effects on the bone microstructure.

Sign in / Sign up

Export Citation Format

Share Document